通讯作者: 郑吉善, zjs22@163.com

DOI：10.12201/bmr.202509.00001

Efficacy analysis of doxycycline in the treatment of Mycoplasma Pneumoniae Pneumonia in children under 8 years old

• 摘要：目的 探讨多西环素治疗8岁以下儿童肺炎支原体肺炎的疗效,初步分析其安全性,为临床合理用药提供依据。 方法 收集2023年7月至2024年6月宁波大学附属妇女儿童医院北部院区儿科收治的258例年龄小于8岁的肺炎支原体肺炎患儿的临床资料。根据是否使用多西环素分为阿奇霉素组(n=156)和多西环素组(n=102),比较两组患儿治疗前后各项临床指标、炎症相关指标、肝功能指标及不良反应情况。 结果 治疗后多西环素组退热时间、咳嗽缓解时间、肺炎影像吸收时间及住院时间均短于阿奇霉素组(P＜0.05),需使用激素及气管镜干预人数、住院总费用超过10000元人数均少于阿奇霉素组(P＜0.05)；两组C反应蛋白(CRP)、D二聚体(DD)、血清铁蛋白(SF)、乳酸脱氢酶(LDH)较治疗前降低,且多西环素组降低幅度大于阿奇霉素组(P＜0.05)；两组谷丙转氨酶(ALT)、谷草转氨酶(AST)、前白蛋白(PA)治疗前后均无明显变化(P＞0.05)；两组不良反应主要为胃肠道反应,发生率比较无统计学意义(P =0.204)。 结论? 多西环素治疗8岁以下儿童肺炎支原体肺炎可有效缓解临床症状,降低炎症反应,减少激素及气管镜干预几率,缩短住院时间及减少住院费用,使用正规治疗剂量及疗程无严重不良反应发生,安全性良好。

  关键词： 多西环素; 肺炎支原体肺炎; 超说明书用药; 临床疗效

   

  Abstract: OBJECTIVETo explore the efficacy of doxycycline in the treatment of Mycoplasma pneumoniae pneumonia in children under 8 years old, and preliminarily analyze its safety, so as to provide a basis for rational clinical drug use.METHODSThe clinical data of 258 children under 8 years old with Mycoplasma pneumoniae pneumonia admitted to the Department of Pediatrics, Northern Branch of Womens and Childrens Hospital of Ningbo University from July 2023 to June 2024 were collected. According to whether doxycycline was used, they were divided into the azithromycin group (n=156) and the doxycycline group (n=102). The clinical indexes, inflammation - related indexes, liver function indexes and adverse reactions of the two groups of children before and after treatment were compared.RESULTSAfter treatment, the defervescence time, cough relief time, pneumonia image absorption time and hospital stay in the doxycycline group were shorter than those in the azithromycin group(P＜0.05). The number of patients who needed to use steroids and bronchoscope intervention, and the number of patients with total hospitalization costs more than 10,000 yuan were less than those in the azithromycin group(P＜0.05). The C-reactive protein (CRP), D-dimer (DD), serum ferritin (SF) and lactate dehydrogenase (LDH) in both groups decreased compared with those before treatment, and the reduction in the doxycycline group was greater than that in the azithromycin group(P＜0.05). There were no significant changes in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and prealbumin (PA) before and after treatment in both groups(P＞0.05). The main adverse reactions in both groups were gastrointestinal reactions, and there was no significant difference in the incidence rate(P=0.204).CONCLUSIONSDoxycycline can effectively relieve the clinical symptoms, reduce the inflammatory response, decrease the probability of steroids and bronchoscope intervention, shorten the hospital stay and reduce the hospitalization costs in the treatment of Mycoplasma pneumoniae pneumonia in children under 8 years old. There are no serious adverse reactions were observed within the regular treatment dose and course, and the safety is good.

  Key words: doxycycline; Mycoplasma pneumoniae pneumonia; off-label drug use; clinical efficacy

  提交时间：2025-09-01

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• p>何海玲, 陆建良, 冯媛, 卢艳玲. 儿童重症肺炎支原体肺炎的临床特点分析. 2025. doi: 10.12201/bmr.202505.00038

  时小淋, 汤冬静, 吴美慧. 儿童肺炎支原体支气管肺炎和大叶性肺炎的相关危险因素分析. 2025. doi: 10.12201/bmr.202507.00035

  王媛媛, 常艳美, 于丽娟, 孟淑萍. 肺炎支原体RNA检测在儿童肺炎支原体肺炎诊断和治疗中的价值研究. 2025. doi: 10.12201/bmr.202506.00025

  施明杰, 叶洪舟, 袁琛. 大环内酯类耐药肺炎支原体肺炎患儿发展为重症肺炎的危险因素分析及预测模型构建. 2024. doi: 10.12201/bmr.202409.00021

  罗自豪, 耿　刚, 李少军. 儿童肺炎支原体脑炎1例并文献复习. 2024. doi: 10.12201/bmr.202408.00042

  张雪, 李菲凡, 张水堂. 混合感染及耐药基因对肺炎支原体肺炎患儿临床特征的影响差异. 2024. doi: 10.12201/bmr.202412.00025

  刘嘉欣, 张小华, 杨逸彤. CARDS TX在儿童肺炎支原体感染中的研究进展. 2025. doi: 10.12201/bmr.202506.00057

  马亚鑫, 朱晓伟, 李淑琼, 李云翔, 孙永红. 儿童重症肺炎支原体肺炎早期预测的研究进展. 2025. doi: 10.12201/bmr.202504.00073

  陆昕玥, 朱珠, 赵永根, 朱正怡, 陈凌栋, 俞刚. 基于人工智能的儿童抗菌药物超适应症评估系统设计与应用. 2024. doi: 10.12201/bmr.202411.00080

  蔡欣欣, 吴夏阳. 国产与原研药注射用阿奇霉素治疗儿童支原体肺炎有效性与安全性评价. 2025. doi: 10.12201/bmr.202501.00071

• 序号	提交日期	编号	操作
  1	2025-07-22	bmr.202509.00001V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论